These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
9. Another Choice for Prevention of COPD Exacerbations. Donohue JF N Engl J Med; 2016 Jun; 374(23):2284-6. PubMed ID: 27181835 [No Abstract] [Full Text] [Related]
10. Multivalent dual pharmacology muscarinic antagonist and β₂ agonist (MABA) molecules for the treatment of COPD. Hughes AD; McNamara A; Steinfeld T Prog Med Chem; 2012; 51():71-95. PubMed ID: 22520472 [No Abstract] [Full Text] [Related]
11. Review: Combination umeclidinium/vilanterol improved health status more than umeclidinium in COPD. Stanbrook MB Ann Intern Med; 2015 Dec; 163(12):JC10. PubMed ID: 26666800 [No Abstract] [Full Text] [Related]
12. Emerging trends in the therapy of COPD: bronchodilators as mono- and combination therapies. Fitzgerald MF; Fox JC Drug Discov Today; 2007 Jun; 12(11-12):472-8. PubMed ID: 17532532 [TBL] [Abstract][Full Text] [Related]
17. An integrated approach to the medical treatment of chronic obstructive pulmonary disease. Rosenberg SR; Kalhan R Med Clin North Am; 2012 Jul; 96(4):811-26. PubMed ID: 22793946 [TBL] [Abstract][Full Text] [Related]
18. The use of long acting β₂-agonists, alone or in combination with inhaled corticosteroids, in chronic obstructive pulmonary disease (COPD): a risk-benefit analysis. Cave AC; Hurst MM Pharmacol Ther; 2011 May; 130(2):114-43. PubMed ID: 21276815 [TBL] [Abstract][Full Text] [Related]
19. Advances in drug delivery: Is triple therapy the future for the treatment of chronic obstructive pulmonary disease? Salama RO; Young PM; Rogueda P; Lallement A; Iliev I; Traini D Expert Opin Pharmacother; 2011 Aug; 12(12):1913-32. PubMed ID: 21714776 [TBL] [Abstract][Full Text] [Related]
20. [Dual bronchodilators becomes the first choice combination]. Einecke D MMW Fortschr Med; 2016 Jun; 158(11):18. PubMed ID: 27271388 [No Abstract] [Full Text] [Related] [Next] [New Search]